Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | inositol-1 | 0.0038 | 1 | 1 |
Schistosoma mansoni | inositol monophosphatase | 0.0038 | 1 | 0.5 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0038 | 1 | 0.5 |
Echinococcus multilocularis | inositol monophosphatase 1 | 0.0038 | 1 | 0.5 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0038 | 1 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0016 | 0.2512 | 0.2512 |
Schistosoma mansoni | inositol monophosphatase | 0.0038 | 1 | 0.5 |
Trichomonas vaginalis | inositol monophosphatase, putative | 0.0038 | 1 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0016 | 0.2512 | 0.2512 |
Toxoplasma gondii | inositol(myo)-1(or 4)-monophosphatase 2, putative | 0.0038 | 1 | 0.5 |
Mycobacterium tuberculosis | Inositol-1-monophosphatase SuhB | 0.0034 | 0.8626 | 0.5 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0038 | 1 | 0.5 |
Mycobacterium ulcerans | extragenic suppressor protein SuhB | 0.0038 | 1 | 1 |
Echinococcus granulosus | inositol monophosphatase 1 | 0.0038 | 1 | 0.5 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0016 | 0.2512 | 0.2512 |
Mycobacterium leprae | possible inositol monophosphatase SubH (IMPase) (inositol-1-phosphatase) (I-1-Pase ). | 0.0034 | 0.8626 | 0.5 |
Trypanosoma brucei | inositol-1(or 4)-monophosphatase 1, putative | 0.0038 | 1 | 1 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0038 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | fructose-1,6-bisphosphatase | 0.0038 | 1 | 0.5 |
Leishmania major | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0038 | 1 | 1 |
Entamoeba histolytica | myo-inositol monophosphatase, putative | 0.0038 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.